FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
October 7, 2026
Foley Career Perspectives
Different Strengths, One Team: An Interview With Texas Attorneys of the Year Chris Converse and Chris Babcock
The firm’s collaborative culture was on full display when partners Chris Converse and Chris Babcock worked together on a “rare kind of legal achievement” that required both strategic vision and deep technical analysis.
October 7, 2026
Foley Viewpoints
What Your Software Company Is Worth Now
Rob Bartlett of Jefferies joined the panel I moderated last month on whether companies should buy, sell, or wait. This week I read his team’s monthly software valuation update, with data through September 30. I read a lot of bank decks. This one I read twice.
October 7, 2026
Foley Viewpoints
Beyond Animal Testing: FDA's 2026 Framework for Fit-for-Purpose NAMs
In September 2026, FDA took another significant step toward integrating new approach methodologies, or NAMs, into drug development by issuing a Direct Final Rule on Nonclinical Testing Terminology (the “September 2026 direct final rule”).[